Physician profile
Thomas Kouri
NPI 1568412773
$280.88
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $171 · 2020: $78.56 · 2021: $14.49 · 2022: $17.15.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $37.86 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $35.74 | 2019-2020 | |
| Pfizer INC. | $35.37 | 2019-2020 | |
| Abbott Laboratories | $31.64 | 2021-2022 | |
| Astellas Pharma US INC | $30.72 | 2019 | |
| Allergan, INC. | $29.99 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $15.06 | 2019 | |
| Amgen INC. | $13.59 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.28 | 2019 | |
| Gilead Sciences, INC. | $13.20 | 2019 | |
| Lilly USA, LLC | $13.12 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $11.31 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Kouri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.